Vedolizumab Is Associated With Longer Drug Sustainability Compared to Infliximab in Moderate-To-Severe Ulcerative Colitis: Long Term Real-World Cohort Data

• DOI: 10.20944/preprints202305.2227.v1
• Publication Date: 2023-06-01T00:54:56Z
• Authors: Tom Konikoff; Henit Yanai; Dror Libchik; Irit Avni-Biron; Yifat Snir; Hagar Banai; Yelena Broitman; Iris Dotan; Jacob E Ollech
• Keywords: Vedolizumab

Background & Aim: Drug sustainability (DS) is a surrogate marker for treatment efficacy. We aimed to compare the DS of two main biologics used treat moderate-to-severe ulcerative colitis (UC), infliximab (IFX) and vedolizumab (VDZ), in real-world setting. Methods: conducted retrospective cohort study at tertiary medical center Israel. included patients treated between Dec 1st, 2017, May 2021, who were followed up 300 weeks. was defined as corticosteroid, surgical, hospitalization-free treatment. Results: 217 with UC included. VDZ had significantly longer median 265.6 weeks compared IFX's 106.5 (p=0.001) treatment-naïve patients, even when adjusting disease severity (HR 0.55 95 CI 0.3-0.98, p=0.042). In treatment-experienced comparable IFX (p=0.593). Conclusion: showed IFX, also adjusted severity. There no difference switching from one drug another. may be suitable first-line biologic-naïve UC.